Alzheimer’s disease: are blood and brain markers related? A systematic review: Blood and Brain Markers of Alzheimer’s Disease

TY - JOUR

T1 - Alzheimer’s disease: are blood and brain markers related? A systematic review

T2 - Blood and Brain Markers of Alzheimer’s Disease

AU - Khan, Ali

AU - Dobson, Richard James Butler

AU - Sattlecker, Martina

AU - Kiddle, Steven John

PY - 2016/5/11

Y1 - 2016/5/11

N2 - Objective: Peripheral protein biomarkers of Alzheimer’s disease (AD) may helpidentify novel treatment avenues by allowing early diagnosis, recruitment toclinical trials, and treatment initiation. The purpose of this review was to deter-mine which proteins have been found to be differentially expressed in the ADbrain and whether these proteins are also found within the blood of ADpatients. Methods: A two-stage approach was conducted. The first stageinvolved conducting a systematic search to identify discovery-based brain pro-teomic studies of AD. The second stage involved comparing whether proteinsfound to be differentially expressed in AD brain were also differentiallyexpressed in the blood. Results: Across 11 discovery based brain proteomicstudies 371 proteins were at different levels in the AD brain. Nine proteins werefrequently found, defined as appearing in at least three separate studies. Ofthese proteins heat-shock cognate 71 kDa, ubiquitin carboxyl-terminal hydro-lase isozyme L1, and 2',3'-cyclic nucleotide 3' phosphodiesterase alone werefound to share a consistent direction of change, being consistently upregulatedin studies they appeared in. Eighteen proteins seen as being differentiallyexpressed within the AD brain were present in blood proteomic studies of AD.Only complement C4a was seen multiple times within both the blood and brainproteomic studies. Interpretation: We report a number of proteins appearingin both the blood and brain of AD patients. Of these proteins, C4a may be agood candidate for further follow-up in large-scale replication efforts.

AB - Objective: Peripheral protein biomarkers of Alzheimer’s disease (AD) may helpidentify novel treatment avenues by allowing early diagnosis, recruitment toclinical trials, and treatment initiation. The purpose of this review was to deter-mine which proteins have been found to be differentially expressed in the ADbrain and whether these proteins are also found within the blood of ADpatients. Methods: A two-stage approach was conducted. The first stageinvolved conducting a systematic search to identify discovery-based brain pro-teomic studies of AD. The second stage involved comparing whether proteinsfound to be differentially expressed in AD brain were also differentiallyexpressed in the blood. Results: Across 11 discovery based brain proteomicstudies 371 proteins were at different levels in the AD brain. Nine proteins werefrequently found, defined as appearing in at least three separate studies. Ofthese proteins heat-shock cognate 71 kDa, ubiquitin carboxyl-terminal hydro-lase isozyme L1, and 2',3'-cyclic nucleotide 3' phosphodiesterase alone werefound to share a consistent direction of change, being consistently upregulatedin studies they appeared in. Eighteen proteins seen as being differentiallyexpressed within the AD brain were present in blood proteomic studies of AD.Only complement C4a was seen multiple times within both the blood and brainproteomic studies. Interpretation: We report a number of proteins appearingin both the blood and brain of AD patients. Of these proteins, C4a may be agood candidate for further follow-up in large-scale replication efforts.

U2 - 10.1002/acn3.313

DO - 10.1002/acn3.313

M3 - Article

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

ER -